The HIV-1 regulatory protein, trans-activator of transcription (Tat), interacts with opioids to potentiate neuroinflammation and neurodegeneration within the CNS. These effects may involve the C-C chemokine receptor type 5 (CCR5); however, the behavioral contribution of CCR5 on Tat/opioid interactions is not known. Using a transgenic murine model that expresses HIV-1 Tat protein in a GFAP-regulated, doxycycline-inducible manner, we assessed morphine tolerance, dependence, and reward. To assess the influence of CCR5 on these effects, mice were pretreated with oral vehicle or the CCR5 antagonist, maraviroc, prior to morphine administration. We found that HIV-1 Tat expression significantly attenuated the antinociceptive potency of acute morphine (2-64 mg/kg, i.p.) in non-tolerant mice. Consistent with this, Tat attenuated withdrawal symptoms among morphine-tolerant mice. Pretreatment with maraviroc blocked the effects of Tat, reinstating morphine potency in non-tolerant mice and restoring withdrawal symptomology in morphine-tolerant mice. Twenty-four hours following morphine administration, HIV-1 Tat significantly potentiated ($3.5-fold) morphine-conditioned place preference and maraviroc further potentiated these effects ($5.7-fold). Maraviroc exerted no measurable behavioral effects on its own. Protein array analyses revealed only minor changes to cytokine profiles when morphine was administered acutely or repeatedly; however, 24 h post morphine administration, the expression of several cytokines was greatly increased, including endogenous CCR5 chemokine ligands (CCL3, CCL4, and CCL5), as well as CCL2. Tat further elevated levels of several cytokines and maraviroc pretreatment attenuated these effects. These data demonstrate that CCR5 mediates key aspects of HIV-1 Tatinduced alterations in the antinociceptive potency and rewarding properties of opioids.
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Introduction
There is a dynamic relationship between opioid use, human immunodeficiency virus-1 (HIV-1) acquisition, and disease progression. Worldwide, injection drug use (IDU) accounts for $30% of new HIV-1 infections outside of sub-Saharan Africa (WHO, 2016) . Within the United States, over 3500 new infections involved IDU in 2015 (CDC, 2016), a year in which overall drug overdose deaths rose another 11%, the majority (63%) of which involved opioids (Rudd et al., 2016) . The convergence of the HIV and opioid epidemics is particularly concerning given evidence that opioid usage increases the progression of HIV-1 to acquired immune deficiency syndrome (AIDS) and promotes neurocognitive impairment in humans and non-human primates (Bokhari et al., 2011; Bell et al., 1996 Bell et al., , 2002 Bell et al., , 2006 Chuang et al., 2005; Donahoe et al., 1993; Kumar et al., 2004 Kumar et al., , 2006 Rivera et al., 2013) . Moreover, HIV-infected individuals are at risk for the development of neuropathic pain (Malvar et al., 2015) for which prescription opioids remain a common treatment (Kremer et al., 2016; Zilliox, 2017) . Pharmacological treatment for opioid abuse includes substitution therapies (Moatti et al., 1998; Roux et al., 2008; Sambamoorthi et al., 2000; Woody et al., 2014) , which may exert neurotoxic interactions with HIV-1 proteins (Fitting et al., 2014b) . As such, the mechanisms and physiological consequences of HIV/opioid interactions need to be understood in order to improve outcomes for
